hat

A-485 is a potent and selective catalytic p300 CBP inhibitor with IC50 values of 9.8 nM for p300 and 2.6 nM for CBP.

Acetaminophen (APAP) is a COX inhibitor that inhibits COX-1 and COX-2 (IC50=113.7 25.8 μM). Acetaminophen has antipyretic and analgesic activity as well as weak anti-inflammatory activity.

Curcumin (Natural Yellow 3) is a phenolic natural product, an inhibitor of histone acetyltransferase p300 CREB (IC50=25 μM) with specificity. Curcumin has a wide range of pharmacological activities such as antitumor, anti-inflammatory and antioxidant.

Remodelin is an effective and specific inhibitor of the acetyl-transferase protein NAT10.

CPI-637 is a selective and cell-active benzodiazepinone CBP EP300 bromodomain inhibitor.

Garcinol also inhibits histone acetyltransferases (HATs, IC50= 7 μM) and p300 CPB-associated factor (PCAF, IC50 = 5 μM). Garcinol has anti-inflammatory and anti-cancer activity. Garcinol, a polyisoprenylated benzophenone harvested from Garcinia indica, exerts anti-cholinesterase properties towards acetyl cholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50s of 0.66 μM and 7.39 μM, respectively.

Fexinidazole (HOE 239) is an antiparasitic agent with activity against Trypanosoma cruzi, Tritrichomonas foetus, Trichomonas vaginalis, Entamoeba histolytica, Trypanosoma brucei, and Leishmania donovani. The biologically relevant active metabolites in vivo are the sulfoxide and sulfone.

C646, a histone acetyltransferase inhibitor, inhibits p300 (Ki: 400 nM, in a cell-free assay).

PF-CBP1 hydrochloride (PF-CBP1 HCl) is a highly selective inhibitor of the bromodomain of CREB-binding protein(CREBBP).It inhibits CREBBP and p300 bromodomains with IC50 of 125 and 363 nM respectively.

I-CBP112 is a specific and potent acetyl-lysine competitive protein-protein interaction inhibitor targeting the CBP p300 bromodomains.

Remodelin hydrobromide (Remodelin HBR) is a novel potent and selective inhibitor of the acetyl-transferase protein NAT10.

CPTH2 is a histone acetyltransferase inhibitor modulating Gcn5 network.

HAT-IN-1, an inhibitor of HAT (histone acetyltransferase), is utilized in cancer research.

HAT-SIL-TG-1&AT, a hypoxia-activated prodrug, functions as a Janus tyrosine kinase (JAK) inhibitor demonstrating antitumor effects by inhibiting JAK-STAT signaling within tumor tissues. It also suppresses the proliferation of HEL cells and downregulates phosphorylated STAT3 5 in hypoxic conditions.

HAT-IN-8 (Compound 38), a blood-brain barrier-permeable inhibitor of Trypanosoma brucei with an EC50 of 0.18 μM, is utilized in the study of Human African trypanosomiasis [1].

Humanized anti-tac (HAT) binding peptide is a peptide that specifically binds to the Fc region of HAT. HAT is a humanized monoclonal antibody targeting the low-affinity p55 subunit of the interleukin IL-2 receptor. The peptide can be utilized in the development of affinity chromatography media for the purification of specific monoclonal antibodies.

Sphingosine-1-phosphate (S1P) is an agonist for S1P1-5 receptors and a ligand for GPR3, GPR6, and GPR12. As an intracellular second messenger, it mobilizes Ca2+ and acts as an extracellular ligand for G-protein coupled receptors. This important lipid mediator is generated from sphingosine or other membrane phospholipids.

Dextrorotation nimorazole phosphate ester TFA is an anti-anaerobic and anti-parasitic agent.

Levorotation nimorazole phosphate ester TFA is an anti-anaerobic and anti-parasitic agent.

D-erythrose 4-sodium phosphate is the sodium phosphate of the monosaccharide erythrose. Erythritol is actually converted to D-erythrose 4-phosphate involving three isomerases.

Triciribine phosphate (VD 002) is a highly selective AKT inhibitor that induces cell cycle arrest and cysteinyl asparagin-dependent apoptosis, inhibits neovascularization, and can be used in the study of leukemia.

AICAR monophosphate (Aica ribonucleotide) is a purine precursor with antineoplastic activity and can be used in studies about type 2 diabetes.

6-Acryloyloxyhexyl phosphater (PA21) is a novel phosphate-binding agent, which is an iron-based reagent, and can be used for the treatment of hyperphosphatemia in chronic kidney disease.

Farnesyl Pyrophosphate ammonium (Farnesyl diphosphate ammonium) is a metabolic intermediate of the MVA pathway that acts as a newly identified danger signal to trigger acute cell death and induce neuronal loss in stroke.